KIT exon 11 mutants Inhibitors
1 drugsAbout KIT exon 11 mutants
KIT exon 11 mutants involve constitutively activated KIT, a receptor tyrosine kinase crucial for cell growth, differentiation, and survival signaling pathways. These mutations drive uncontrolled cell proliferation, making them key drivers in specific malignancies.
Targeting KIT exon 11 mutants is clinically significant, but there is currently no genetic evidence available to support this approach. The aberrant signaling caused by these mutations makes them a rational target for therapeutic intervention.
AYVAKIT is the only FDA-approved drug targeting KIT exon 11 mutants, developed by BLUEPRINT MEDICINES. It is a small molecule used across 6 indications in therapeutic areas beyond autoimmune diseases or diabetes.
Top KIT exon 11 mutants Drugs
BLUEPRINT MEDICINES is the only company with an approved drug targeting KIT exon 11 mutants.
The market is highly concentrated, indicating potential entry barriers but also significant unmet need.
KIT exon 11 mutants Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KIT exon 11 mutants, using small molecule modality.
The absence of other modalities suggests a whitespace opportunity for novel approaches like antibodies or PROTACs.
KIT exon 11 mutants Clinical Trials 17 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on KIT exon 11 mutants. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 | 100% |
| Phase 2 | 8 | 1 | 0 | 7 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KIT exon 11 mutants Drug Approval Timeline (2020 - 2020)
AYVAKIT was the first and most recent drug approved in 2020, representing a 1-year span.
The recent approval and lack of subsequent drugs suggest an emerging but not yet saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on KIT exon 11 mutants. A trial counts if an approved drug acting on KIT exon 11 mutants is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.